Poolbeg Pharma has received notification from the Canadian Patent Office of its decision to grant the company’s POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (CRS) patent application. This comes shortly after the first national grant within Poolbeg’s cancer immunotherapy-induced CRS patent family, demonstrating strong momentum in expanding this family globally and further strengthening the IP position for POLB. The claims cover the use of any p38 MAPK inhibitor, including POLB ....